Clinical Trials - Columbus NCI Community Clinical Oncology Research Program

Phone: 614/488-2118
Fax: 614/488-2647

1335 Dublin Rd., Suite 124A
Columbus, OH 43215

Protocol Categories

View All Protocols

Hematology

Alliance A041702

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

ECOG EAA171

Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)

ECOG EAA173

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

ECOG EAA181

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

ECOG NHLBI-MDS

The National Myelodysplastic Syndromes (MDS) Study

NCI COVID-19

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

OSU 2010-C0126 Buckeye Surveillance

Buckeye Surveillance, Contact, and Research for MGUS, Myeloma and Amyloidosis

SWOG S1712

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

SWOG S1803

Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

SWOG S1925

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Protocol Categories

Hematology

Our Organization

Members